Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Mechanisms of antiaddictive actions of ibogaine.

Glick SD, Maisonneuve IS.

Ann N Y Acad Sci. 1998 May 30;844:214-26. Review.

PMID:
9668680
2.

Development of novel medications for drug addiction. The legacy of an African shrub.

Glick SD, Maisonneuve IM.

Ann N Y Acad Sci. 2000;909:88-103.

PMID:
10911925
3.

18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.

Glick SD, Maisonneuve IM, Szumlinski KK.

Ann N Y Acad Sci. 2000 Sep;914:369-86.

PMID:
11085336
4.

18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats.

Glick SD, Kuehne ME, Maisonneuve IM, Bandarage UK, Molinari HH.

Brain Res. 1996 May 6;719(1-2):29-35.

PMID:
8782860
5.

Ibogaine-like effects of noribogaine in rats.

Glick SD, Pearl SM, Cai J, Maisonneuve IM.

Brain Res. 1996 Mar 25;713(1-2):294-7.

PMID:
8725004
6.
7.

Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats.

Wei D, Maisonneuve IM, Kuehne ME, Glick SD.

Brain Res. 1998 Aug 3;800(2):260-8.

PMID:
9685673
8.
9.
10.

Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.

Maisonneuve IM, Glick SD.

Pharmacol Biochem Behav. 2003 Jun;75(3):607-18.

PMID:
12895678
11.

Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine.

Glick SD, Maisonneuve IM, Pearl SM.

Brain Res. 1997 Feb 28;749(2):340-3.

PMID:
9138735
12.

18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats.

Glick SD, Maisonneuve IM, Visker KE, Fritz KA, Bandarage UK, Kuehne ME.

Psychopharmacology (Berl). 1998 Oct;139(3):274-80.

PMID:
9784085
13.

Iboga interactions with psychomotor stimulants: panacea in the paradox?

Szumlinski KK, Maisonneuve IM, Glick SD.

Toxicon. 2001 Jan;39(1):75-86. Review.

PMID:
10936624
14.
15.

Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors.

Sershen H, Hashim A, Lajtha A.

Brain Res Bull. 1997;42(3):161-8. Review.

PMID:
8995326
16.

Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine.

Maisonneuve IM, Glick SD.

Eur J Pharmacol. 1999 Oct 21;383(1):15-21.

PMID:
10556676
17.

Inhibitory effects of ibogaine on cocaine self-administration in rats.

Cappendijk SL, Dzoljic MR.

Eur J Pharmacol. 1993 Sep 14;241(2-3):261-5.

PMID:
8243561
18.

The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus.

Helsley S, Filipink RA, Bowen WD, Rabin RA, Winter JC.

Pharmacol Biochem Behav. 1998 Feb;59(2):495-503.

PMID:
9477000
19.

Modulation of morphine-induced antinociception by ibogaine and noribogaine.

Bagal AA, Hough LB, Nalwalk JW, Glick SD.

Brain Res. 1996 Nov 25;741(1-2):258-62.

PMID:
9001731
20.

Role of oxytocin in the neuroadaptation to drugs of abuse.

Sarnyai Z, Kovács GL.

Psychoneuroendocrinology. 1994;19(1):85-117. Review.

PMID:
9210215

Supplemental Content

Support Center